profit from procurement

MEDInstill and Institut Pasteur de Dakar, Senegal, reach pioneering Fill-Finish agreement

16/09/2021

It is with great pleasure that I am able to update my previous article, ‘Turning Vaccines into Vaccinations’.

In it, I mentioned that INTACT Solutions (a wholly owned subsidiary of MEDInstill) had partnered with CEPI to explore the use of INTACT™ multi-dose pouches and multi-dose syringes to meet the challenge of distributing and delivering billions of doses of vaccines equitably and quickly around the world.

I am delighted to say that equitable access to vaccines has taken a step forward through a pioneering fill-finish deal reached between MEDInstill and Senegal’s Institut Pasteur de Dakar (IPD) .

IPD’s aim is to produce 300 million COVID-19 vaccines per year by the end of 2022 and will start by focussing on the fill-finish process: hence the deal with MEDInstill.

The fill-finish process is a well-known bottleneck in the manufacture of vaccines. It considerably slows down vaccine availability and this delay is literally costing lives while the COVID19 pandemic continues.

By using MEDInstill’s ground-breaking closed, sterile fill, connect and deliver INTACT™ technology, IPD will be able to produce vaccines considerably faster, safer and more cost-effectively than any other existing aseptic technology on the market.

INTACT™ multi-dose pouches will revolutionise the fill/finish process in vaccine production. Each pouch holds 200 doses of vaccine (scalable up and down).

Instead of being restricted to filling small glass vials using traditional aseptic fillers, IPD will be able to fill INTACT™ Multi-dose pouches at a rate of 4,000 doses per minute using MEDInstill’s INTACT™ Environment Independent Filling Line (EIFL).

Please click on the following link to see the EIFL in operation:

INTACT™ Environment Independent Filling Line

Not only do these pouches entirely overcome the fill-finish bottleneck, should they be adopted more widely by vaccine producers, they would completely eradicate the threat posed to glass vial production and vaccine availability caused by the global shortage of glass.

Through this deal, IPD and MEDInstill are not only assisting in the reduction of Africa’s dependency on vaccine imports, they are also taking an important step closer to delivering equitable access of vaccines to all.

If you would like further information about INTACT Solutions and INTACT™ technology, please contact me via email: douglas@supplysidefocus.com or mob: 07941 772153

Back to news